The financing for the Paris-based company, which has its U.S. base in Cambridge, Massachusetts, includes $34 million (€30 million) from a Series D2 financing, alongside $34 million (€30 million) from a European Investment Bank (EIB) financing facility.
According to Tissium, the financing comes amid a “transformational stage” for the company. It received FDA authorization for its Coaptium Connect with Tissium Light, a first-of-its-kind atraumatic sutureless solution for peripheral nerve repair, last year. The company began its commercial entry into the U.S. and said it continues to make progress across a pipeline of products addressing unmet needs in atraumatic nerve repair, atraumatic hernia repair and cardiovascular applications.
Tissium said it completed the Series D2 round at the end of 2025, with participation from new and existing investors. It said the funding further strengthens its shareholder base and provides capital to support its commercial and clinical activities. The funds also support pipeline development and platform expansion.
Additionally, the EIB funding supports research, innovation and development of transformative healthcare technologies. The facility includes three €10 million tranches linked to commercial, clinical and financing milestones, mixing dilutive and venture debt financing. Tissium expects to draw the first €10 million tranche before the end of June 2026.
Altogether, the company expects its new financing package to provide strategic flexibility amid the Coaptium Connect rollout.
Christophe Bancel, CEO and co-founder, Tissium, said:
“This financing marks an important milestone in Tissium’s evolution. Following the FDA marketing authorization of Coaptium Connect, we are now executing on our transition into a commercial-stage medtech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform. The support of both leading international investors and the European Investment Bank reflects confidence in our technology, our strategy and our ability to bring meaningful innovation to patients. This financing provides the capital and strategic flexibility required to accelerate commercial execution while continuing to invest in the future growth of our platform.”
